62 results about "Serum reaction" patented technology

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.

The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

The invention discloses an epitope of rheumatoid arthritis and application thereof, belonging to the technical field of immunologic diagnosis. The epitope is a polypeptide, and the amino acid sequence is disclosed as SEQ ID NO:1 in the sequence table. ELISA detection and patient serum reaction condition indicate that the epitope polypeptide can be specifically combined with IgG in the patient serum, and does not react with the serum of a health person. The epitope polypeptide can be used for preparing medicines for diagnosing rheumatoid arthritis.

The inventors have discovered an elevated serum response to CBir1 flagellin in Crohn's disease patients. The present invention relates to methods for diagnosis and treatment of Crohn's disease and/or subtypes of Crohn's disease. Diagnosis is accomplished by determining the presence of the anti-CBir1 expression or determining the presence of anti-CBir1 expression and detection of the presence of pANCA. Treatment methods include antigen-directed therapy targeting CBir1 flagellin and manipulating the bacteria in the colon and/or small intestine.

The present invention provides novel, isolated, tumor-associated antigens, and methods for identifying such antigens in a biological sample, and of screening for the presence of such an antigen in a biological specimen, wherein the tumor antigen identified reacts with serum from a subject treated with a vaccine comprising a cytokine and proliferation-incompetent tumor cells which express the tumor-associated antigen. Also provided are kits for carrying out the methods of the invention.

The invention relates to gene engineering and antibody preparation and specifically discloses a preparation method and application of a high-throughput fully-humanized antibody. The preparation methodcomprises the following steps: separating peripheral blood monouclear cells; separating single cells of plasma cells or antigen-specificity memory B blymphocytes; amplifying the heavy-chain and light-chain gene variable regions of single B cell antibody by use of a primer provided by the inventor; establishing an expression system containing antibody heavy-chain and light-chain genes by use of alinear expression system containing a heavy-chain fragment or light-chain fragment constant area; finally, separating and purifying a fully humanized monoclonal antibody. By adopting the primer combination provided by the invention to amplify the genes in the antibody heavy-chain and light-chain variable areas, natural pairing of the light-chain and heavy-chain variable areas can be maintained, and the preparation method has the advantages of high gene diversity, high titer, full humanization, high antibody affinity, strong specificity, no heterologous serum reaction, no risk of propagating other infectious diseases, etc.

The invention discloses an epitope of systemic lupus erythematosus and an application thereof, belonging to the technical field of immunology diagnosis. The epitope is a polypeptide of which the amino acid sequence is shown as a sequence table SEQ ID NO:1. As proved by ELISA (Enzyme-Linked Immunosorbent Assay) detection and the serum reaction condition of a patient, the epitope polypeptide can be specifically combined with IgG (Immunoglobulin G) in the serum of the patient without reacting with the serum of a healthy person. The epitope polypeptide can be used for preparing a medicament for diagnosing systemic lupus erythematosus.

The invention discloses a reagent box for detecting hydrophobia neutralizing antibody competition ELISA of human beings and animals, wherein the reagent box can easily, quickly, accurately and quantitatively detect the hydrophobia neutralizing antibody in blood serums of human beings and animals by marking the hydrophobia neutralizing antibody, the standard serum and the envelope antigen. By using hydrophobia virosome or virus glycoprotein to coat enzyme synapticulae, the enzyme labeling hydrophobia neutralizing antibody is mixed with the blood serum to be tested and the standard serum respectively according to a certain ratio and reacts with the hydrophobia virus glycoprotein antigen coated on the enzyme synapticulae, a standard curve is drawn according to the OD value of the standard blood serum reaction and the known neutralizing titer after the color development, and the titer of the corresponding neutralizing antibody is obtained from the standard curve according to the OD value of the reaction of the blood serum to be tested. The reagent box has the advantages of accurately and quantitatively detecting the neutralizing antibody of the hydrophobia virus, along with simple operation and short time; moreover, the test result of the invention keeps a good consistence with test results of neutralizing test methods recommended by WHO and OIE.

The invention discloses a immune imprinting regent box of the rheumatism self antibody which includes the print film in the reacting slot, the enzyme linked regent, the color regent A liquid, the color regent B liquid, the stop liquid, the condense washing solution and the standard band. Firstly, the ENA is divided by the SDS-polyacrylamide gel electrophoresis according to the molecular weight, then transfers it into the print membrane by the print technology which includes the ENA arrayed by the molecular weight; if the detected blood serum has the self antibody, it will disappear the color band by adding the enzyme linked and the color regent after combining with the according antigen. So it can detect that if the serum has the antibody of Sm, U1RNP,ssA,ssB,Scl-70,Jo-1,Ro60,Rib to diagnose and identify the rheumatism.

The present invention provides a 120-kDa protein gene of Ehrlichia canis, amplified by PCR using primers derived from the DNA sequences flanking the Ehrlichia chaffeensis 120-kDa protein gene. The recombinant E. canis 120-kDa protein contains 14 tandem repeat units with 36 amino acids each. The repeat units are hydrophilic and predicted to be surface-exposed. Also disclosed is that the recombinant E. canis 120-kDa protein is antigenic and reacts with sera from dogs convalescent from canine ehrlichiosis.

The invention features methods and compositions for reducing the serum C-reactive protein (CRP), IL-6, and/or IFN-γ levels in a patient in need thereof, and for treating diseases and conditions associated with an increased serum CRP, IL-6, and/or IFN-γ levels. The invention also features methods and compositions for treating a patient diagnosed with, or at risk of developing, periodontal disease by administering a corticosteroid or an analog thereof and/or a tetra-substituted pyrimidopyrimidine or an adenosine analog upregulator.

The invention discloses a competitive enzyme-linked immunosorbent assay method of an EV71 neutralizing antibody, a kit or a reagent and a preparation method thereof. The kit utilizes the labeled monoclonal antibody which has higher neutralizing potency on three genes of A, B and C of EV71 virus, a reference material of the EV71 neutralizing antibody and a coated plate and can simply, rapidly and accurately carry out qualitative and quantitative assay on the content of the EV71 neutralizing antibody in a human sample or an animal sample. EV71 virus particles are coated on the ELISA plate, the enzyme-labeled EV71 neutralizing antibody is diluted according to a certain proportion, then respectively mixed with the sample to be assayed and the reference material of the EV71 neutralizing antibody and reacted with an EV71 antigen coated on the ELISA plate, a semi-logarithmic standard curve is drawn according to the absorptance percentage of OD value of the reference serum reaction and the logarithm of the potency of the reference material of the EV71 neutralizing antibody after color development, and the absorptance percentage of the OD value of the sample to be assayed is substituted ina standard curve equation to calculate the corresponding neutralizing potency.

This invention discloses one diabetes disease self antigen print agent case, whose islets of Langerhans cell extracts mixture protein composed of Langerhas element, glutamic acid decarboxylase and Langerhas cell; using protein print technique through SDS-polyacrylamide gel electrophoresis ranked by molecule size then into print film; its film bar comprises molecule of each Langerhans self antigen element to be put into reaction tank and serum; if it has antigen, then processing antigen combination and then adding enzyme cross and development agent in the zone; comparing with standard to judge whether serum has the antigen etc.

The invention discloses application of mycoplasma bovis secretory protein MbovP274 in preparation of mycoplasma bovis diagnostic reagents, drugs or vaccines, and belongs to the technical field of animal infectious disease prevention and treatment. The mycoplasma bovis secretory protein MbovP274 has an amino acid sequence as shown in SEQ ID NO: 2; gene annotation information shows that the amino acid sequence is a functionally-unknown protein; and experiments show that the MbovP274 protein has antigenicity and can react with mycoplasma bovis positive serum instead of mycoplasma bovis negative serum; the MbovP274 protein is identified as a secretory protein through western blot; it is further verified that the protein can induce bovine macrophages to highly express IL-8 and IFN-gamma, the IL-8 is an important neutrophil activating factor, and the IFN-gamma is a wide immunomodulatory factor. According to the research, the MbovP274 is considered to be an important pathogenic factor of mycoplasma bovis and can activate host immunity, and has important potential in research and development of new drugs and vaccines.

The invention discloses application of mycoplasma bovis secretory protein MbovP570 in preparation of mycoplasma bovis diagnostic reagents, drugs or vaccines, and belongs to the technical field of animal infectious disease prevention and treatment. The mycoplasma bovis secretory protein MbovP570 has a sequence as shown in SEQ ID NO: 1. 2 is an amino acid sequence shown in the specification; test proves that the mycoplasma bovis secretory protein MbovP570 has antigenicity and can be used for detecting mycoplasma bovis. The protein can react with mycoplasma bovis positive serum instead of mycoplasma bovis negative serum, the protein can induce bovine macrophages to highly express IL-8 and IL-12, IL-8 can activate neutrophils, and IL-12 can activate NK cells and T cells. Therefore, it is believed that MbovP570 can activate a host immune system and has important potential in research and development of new drugs and vaccines.

The present disclosure provides compositions and methods for the prevention of HSV infection in an HSV seronegative individual and for the treatment and prevention of recurrence in an HSV seropositive individual.

The invention belongs to the field of biomedicine, providing a method for detecting animal pathogenic microorganisms and a special protein chip thereof. The detecting method essentially comprises the following steps of: a. preparing the protein chip, selecting a plurality of different groups of specific antigen of many kinds of pathogenic microorganisms by means of an experiment to be fixed on a properly modified carrier; and b. detecting: reacting blood serum of a animal to be detected with the protein chip, hybridizing with a marked secondary antibody, detecting a hybrid positive signal in a proper detection way, and obtaining a hybrid result of the blood serum and the chip by means of scanning and analyzing, wherein the blood serum infected with the different pathogenic microorganisms can show different positive signal combination modes after the reaction, so as to ensure whether the animal to be detected is infecting or is infected with the pathogenic microorganisms marked on the protein chip. The invention can simultaneously detect many kinds of the pathogenic microorganisms, improves detecting efficiency, selects many groups of different antigen with a certain specificity aiming at each pathogenic microorganism, leads the detection to have good specificity, and has good application prospect in detecting the animal pathogenic microorganisms.

The invention discloses the usage of TolC protein. The TolC has strong serum reaction, is used to detect and diagnose dysentery, and is used as protective antigens to prepare vaccine.

A specific protein reaction detection method comprises the following steps: respectively carrying out C-reactive protein detection on a serum sample, a plasma sample and a blood sample of the same collection source to obtain specific protein reaction curves of the serum sample, the plasma sample and the blood sample, respectively acquiring curve characteristics of the serum sample, the plasma sample and the blood sample and inputting the curve characteristics into a serum reaction mathematical model, a plasma reaction mathematical model and a blood reaction mathematical model so as to acquireC-reactive protein concentration values cS and cP output of the serum sample and the plasma sample, and then acquiring an HCT detection value Hb of the blood sample; and performing HCT correction on the C-reactive protein concentration value cb' output by the blood reaction mathematical model, and taking the C-reactive protein concentration value cb' obtained after HCT correction as output. The C-reactive protein concentration values of different samples are obtained by obtaining the characteristics of the specific protein reaction curves of the different homologous samples, so that the different homologous samples keep consistent C-reactive protein detection results on the same detection equipment.

The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular N. meningitidis. The SBA assay is the most important method for measuring functional activity of serum antibodies against meningococcus. In order to determine whether a subject or a population is seropositive against invasive meningococcus the SBA test should ideally be both sensitive and specific. The inventors have found the standard N. meningitidis serotype A and W SBAs can be significantly improved in this regard.

Methods and compositions are disclosed for improving vaccination in a subject with preexistent antibodies to the antigenic component of the immunizing vaccine. By temporarily sequestering, disabling, and/or suppressing preexistent antibodies and/or Fc-mediated mechanisms according to the various example embodiments, the target antigenic component of a vaccine has an increased opportunity to enter antigen-presenting cells through the same pathway that it would use in seronegative subjects. A balanced immune environment is thereby restored and B cells are properly activated to produce antigen-specific antibodies following vaccination.

The invention belongs to the technical field of animal infectious disease prevention and control, and in particular relates to a secretory adhesion protein MbovP58 of mycoplasma bovis. The nucleotidesequence of the gene of the protein is shown as SEQ ID NO:1, and the amino acid sequence encoded by the protein is shown as SEQ ID NO:2. According to codon preference of escherichia coli, an Mbov_0581gene is mutated, and the sequence of the mutated Mbov_0581 gene is shown as SEQ ID NO:3. The protein is proved to be a secretory protein by an immune transfer printing method and can react with infected bovine serum. Adhesion of a recombinant protein rMbovP581 expressed in escherichia coli to embryonic bovine lung cells (EBL) is detected by immunofluorescence assay and flow cytometry, and it is found that the MbovP581 has good adhesion to the EBL cells. Through integration of the secretion characteristics, immunogenicity and adhesion of the protein, the protein is expected to be applied to preparation of mycoplasma bovis diagnostic reagents, medicaments and vaccines.